Luseogliflozin
- 1 lab in 1 country
- Funder: Taisho Toyama Pharmaceutical Company
- Human trial1
- Humans1
Outcomes
2Liver stiffness
downin humans1
1 study
Liver stiffness
downin humans1
Luseogliflozin decreases liver stiffness in humans.
Human trialadded to semaglutide in type 2 diabetes and MASHliver52 weeks
Diabetes, obesity & metabolism17 Aug 2026
MASH resolution without worsening fibrosis
no changein humans1
1 study
MASH resolution without worsening fibrosis
no changein humans1
Luseogliflozin has no effect on MASH resolution without worsening fibrosis in humans (34.9% vs 19.4%).
Human trialadded to semaglutide in type 2 diabetes and MASHliver52 weeks
Diabetes, obesity & metabolism17 Aug 2026
Latest
3 in 12 monthsDiabetes, Obesity & Metabolism
Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial
Randomised trial in 60 peopleMetabolic dysfunction-associated steatohepatitis
ADA Scientific Sessions 2026 Abstract
Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)
Trial in peopleInterventions
AAIC 2025 Abstract
SGLT2 Inhibition Protects Cognitive Function in Alzheimer's Disease by Enhancing Brain Perfusion, Independent of Glucose Control
Experiments in animalsInterventions
The Lancet Diabetes & Endocrinology
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Cohort study of 65,231 peopleSGLT2 inhibitors